U266 Cells

Unit

5 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Myeloma cell lines

Organism

Human

Donor History

Multiple Myeloma

Growth Properties

Suspension

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% heat-inactivated FBS. Seeding density: 5 x 10⁵ cells/mL. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/U266-Cells/300259

SKU: 300259 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

The U266 cell line, also known as U-266, is a human multiple myeloma cell line that was established from the peripheral blood of a 53-year-old man with IgE myeloma. This cell line is characterized by the secretion of both light and heavy immunoglobulin chains, predominantly lambda light chains and IgE heavy chains. The U266 cell line exhibits typical B lymphocyte markers and has been used extensively in the study of myeloma biology, particularly in understanding the pathophysiological mechanisms of plasma cell malignancies and the immune response.

U266 cells are valuable for their role in drug discovery and development, providing a robust model for evaluating the efficacy of anti-myeloma agents. They are also utilized in the study of myeloma cell interactions with the bone marrow microenvironment, which is crucial for understanding myeloma progression and resistance to therapy. Genetic studies have revealed several chromosomal abnormalities in U266 cells, which contribute to their malignant phenotype and resistance to apoptosis. This cell line has been instrumental in the advancement of molecular targeted therapies in multiple myeloma.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.